Kailera eyes record $533M+ IPO to play in competitive obesity space with Chinese drugs
Kailera Therapeutics is advancing a pipeline of obesity drugs, led by the GLP-1/GIP dual agonist ribupatide, which the biotech is developing both as an injectable and as a pill.
Kailera eyes record $533M+ IPO to play in competitive obesity space with Chinese drugs Read More »
